Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-α pharmacology.

Inhibitor-of-apoptosis (IAP) proteins suppress apoptosis and are overexpressed in a variety of cancers. Small-molecule IAP antagonists are currently being tested in clinical trials as novel cancer therapeutics. GDC-0152 is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing IAPs. GDC-0152 induces NF-κB transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-α) is the most important for single-agent tumor activity. TNF-α is a pleiotropic cytokine that drives a variety of cellular responses, comprising inflammation, proliferation, and cell survival or death depending on the cellular context. As malignant and normal cells produce TNF-α upon IAP antagonism, increased TNF-α could drive both efficacy and toxicity. The toxicity profile of GDC-0152 in dogs and rats was characterized after iv dose administration once every 2 weeks for four doses. Findings in both species consisted of a dose-related, acute, systemic inflammatory response, and hepatic injury. Laboratory findings included elevated plasma cytokines, an inflammatory leukogram, and increased liver transaminases with histopathological findings of inflammatory infiltrates and apoptosis/necrosis in multiple tissues; a toxicology profile consistent with TNF-α-mediated toxicity. Dogs exhibited more severe findings than rats, and humans did not exhibit these findings, at comparable exposures across species. Furthermore, elevations in blood neutrophil count, serum monocyte chemoattractant protein-1, and other markers of inflammation corresponded to GDC-0152 exposure and toxicity and thus may have utility as safety biomarkers.

[1]  J. Ware,et al.  Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  Zhaoyang Wen,et al.  Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). , 2012, Journal of medicinal chemistry.

[3]  A. Tolcher,et al.  Abstract A25: Phase 1 PK/PD analysis of the Smac-mimetic TL32711 demonstrates potent and sustained cIAP1 suppression in patient PBMCs and tumor biopsies. , 2011 .

[4]  A. Schier,et al.  Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis. , 2011, Neoplasia.

[5]  L. Diaz,et al.  Systemic use of tumor necrosis factor alpha as an anticancer agent , 2011, Oncotarget.

[6]  Vishva M. Dixit,et al.  Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death , 2011, Nature Reviews Molecular Cell Biology.

[7]  S. Morris,et al.  Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Vučić,et al.  Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets. , 2011, Future oncology.

[9]  W. Fujibuchi,et al.  Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer , 2011, Surgery Today.

[10]  P. Vandenabeele,et al.  Molecular mechanisms of necroptosis: an ordered cellular explosion , 2010, Nature Reviews Molecular Cell Biology.

[11]  Jeffrey W. Clark,et al.  Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value , 2010, Clinical Cancer Research.

[12]  Pascal Meier,et al.  IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer , 2010, Nature Reviews Cancer.

[13]  J. Tarrant,et al.  Blood Cytokines as Biomarkers of In Vivo Toxicity in Preclinical Safety Assessment: Considerations for Their Use , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[14]  D. Porter,et al.  Abstract 2775: A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer , 2010 .

[15]  W. Fairbrother,et al.  Small-molecule pan-IAP antagonists: a patent review , 2010, Expert opinion on therapeutic patents.

[16]  L. Kadouri,et al.  The Oncolytic Activity of Newcastle Disease Virus NDV-HUJ on Chemoresistant Primary Melanoma Cells Is Dependent on the Proapoptotic Activity of the Inhibitor of Apoptosis Protein Livin , 2009, Journal of Virology.

[17]  M. Koukourakis,et al.  Serum C-reactive Protein (CRP) Levels in Cancer Patients are Linked with Tumor Burden and are Reduced by Anti-hypertensive Medication , 2009, Inflammation.

[18]  Judith Horner,et al.  A Comparative Analysis of Acute-phase Proteins as Inflammatory Biomarkers in Preclinical Toxicology Studies: Implications for Preclinical to Clinical Translation , 2009, Toxicologic pathology.

[19]  G. Torzilli,et al.  Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma , 2009, BMC Cancer.

[20]  J. Waring,et al.  Both cIAP1 and cIAP2 regulate TNFα-mediated NF-κB activation , 2008, Proceedings of the National Academy of Sciences.

[21]  David L. Vaux,et al.  IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis , 2007, Cell.

[22]  Y. Bayraktar,et al.  Budd-Chiari syndrome: etiology, pathogenesis and diagnosis. , 2007, World journal of gastroenterology.

[23]  Vishva M Dixit,et al.  IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. , 2007, Cell.

[24]  Vinay Tergaonkar,et al.  IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. , 2007, Cell.

[25]  P. Eckersall,et al.  Acute phase proteins in dogs and cats: current knowledge and future perspectives. , 2005, Veterinary clinical pathology.

[26]  A. Ashkenazi,et al.  Tumor Necrosis Factor An Apoptosis JuNKie? , 2004, Cell.

[27]  J. Jura,et al.  Complex analysis of genes involved in the inflammatory response: interleukin-1-induced differential transcriptome of cultured human hepatoma HepG2 cells. , 2003, Acta biochimica Polonica.

[28]  V. Tong,et al.  Kupffer cell-mediated cytotoxicity induced by lipopolysaccharide0111:B4 is greater in dogs than in rats and monkeys. , 2002, The Journal of toxicological sciences.

[29]  M. Netea,et al.  Circulating cytokines as mediators of fever. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  K. Walley,et al.  Decrease in left ventricular contractility after tumor necrosis factor-alpha infusion in dogs. , 1994, Journal of applied physiology.

[31]  A. Gearing,et al.  Clinical applications of cytokines : role in pathogenesis, diagnosis, and therapy , 1993 .

[32]  J. Gérain,et al.  High serum levels of TNF-α after its administration for isolation perfusion of the limb , 1992 .

[33]  J. Gérain,et al.  High serum levels of TNF-alpha after its administration for isolation perfusion of the limb. , 1992, Cytokine.

[34]  G. T. Budd,et al.  Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[35]  C. Natanson,et al.  TNF but not IL-1 in dogs causes lethal lung injury and multiple organ dysfunction similar to human sepsis. , 1991, Journal of applied physiology.

[36]  J. Adams,et al.  hypotension: Implications for the involvement of nitric oxide , 2022 .

[37]  Jiahuai Han,et al.  Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level [published erratum appears in J Exp Med 1990 Mar 1;171(3):971-2] , 1990, The Journal of experimental medicine.

[38]  C. Natanson,et al.  Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock , 1989, The Journal of experimental medicine.

[39]  W. Lautt,et al.  Hepatic venous resistance site in the dog: localization and validation of intrahepatic pressure measurements. , 1987, Canadian journal of physiology and pharmacology.

[40]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[41]  J. Gamble,et al.  Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Craddock Corticosteroid-induced lymphopenia, immunosuppression, and body defense. , 1978, Annals of internal medicine.

[43]  E. D. Jacobson,et al.  Mesenteric vascular responses to endotoxin in the monkey and dog. , 1970, The American journal of physiology.

[44]  D. Sutton,et al.  Pathophysiology of endotoxin shock in the primate. , 1970, American journal of obstetrics and gynecology.